Clinical Trials on Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8

Total 755 results

  • Mayo Clinic
    National Cancer Institute (NCI)
    Suspended
    Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
    Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions
    United States
  • Neonc Technologies, Inc.
    Recruiting
    Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions
    United States
  • Incyte Corporation
    Completed
    A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Stomach Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastroesophageal Junction Cancer | Urothelial... and other conditions
    United States
  • Incyte Biosciences International Sàrl
    Completed
    A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
    Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions
    United States
  • Medicenna Therapeutics, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
    Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions
    United States, Australia, Korea, Republic of, Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe